First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Novartis AG

    NVS · 16 developments mapped · last assessed 2026-09-24

    Market Ontology has mapped 16 macro, policy, and market developments to Novartis AG since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for NVS yet, so no modelled value is shown. The NVS valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run NVS on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for NVS. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial

      Successful Phase III trial for a novel drug in a significant market (MS) increases future revenue potential and strengthens pipeline. Reduces R&D risk.

      · Moves probability of success for pipeline assets, peak sales estimates for remibrutinib, discount rate (due to reduced risk)

    • Main threat

      Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint

      Direct R&D failure, loss of potential future revenue stream from a key pipeline asset.

      · Moves probability of success for pipeline assets, peak sales estimates for pelacarsen, discount rate reflecting r&d risk

    • Open question

      FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA

      Increased competition in the Spinal Muscular Atrophy (SMA) market. Similar to Biogen, Novartis's SMA treatment may face altered market dynamics due to a new combination therapy option.

      · Moves market share for zolgensma (sma gene therapy), pricing power in the sma market

    What changed, by assumption

    Probability of success for pipeline assets
    • 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
    • 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
    • 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
    • 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
    Probability of success
    • 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
    Long term growth rate for oncology segment
    • 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
    Peak sales estimates for zolgensma
    • 2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    • 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
    Market share for zolgensma (onasemnogene abeparvovec)
    • 2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
    • 2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophy

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-24Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026watch3-12m0.20
    2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthBullish1-5y0.60
    2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyBearish3-12m0.50
    2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAmixed3-12m0.30
    2026-09-13FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapymixed3-12m0.30
    2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophywatch3-12m0.30
    2026-09-12FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAwatch3-12m0.30
    2026-09-12FDA Approves Isembyld for Spinal Muscular AtrophyBearish1-3m0.40
    2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapyBearish1-3m0.40
    2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophymixed3-12m0.30
    2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointBearish1-3m0.80
    2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MBearish1-3m0.70